Comprehensive profiling of the human fecal proteome from IBD patients with DIA‐MS enables evaluation of disease‐relevant proteins

Brandon J. Harder,Annemarie N. Lekkerkerker,Ellen P. Casavant,Jason A. Hackney,Allen Nguyen,Jacqueline M. McBride,William Rodney Mathews,Veronica G. Anania
DOI: https://doi.org/10.1002/prca.202300075
2024-03-30
PROTEOMICS - CLINICAL APPLICATIONS
Abstract:Purpose Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is characterized by chronic gastrointestinal inflammation. A high unmet need exists for noninvasive biomarkers in IBD to monitor changes in disease activity and guide treatment decisions. Stool is an easily accessed, disease proximal matrix in IBD, however the composition of the IBD fecal proteome remains poorly characterized. Experimental Design A data‐independent acquisition LC‐MS/MS approach was used to profile the human fecal proteome in two independent cohorts (Cohort 1: healthy n = 5, UC n = 5, CD n = 5, Cohort 2: healthy n = 20, UC n = 10, and CD n = 10) to identify noninvasive biomarkers reflective of disease activity. Results 688 human proteins were quantified, with 523 measured in both cohorts. In UC stool 96 proteins were differentially abundant and in CD stool 126 proteins were differentially abundant compared to healthy stool (absolute log2 fold change > 1, p‐value
biochemical research methods
What problem does this paper attempt to address?